Dr. Egan[/caption]
James Egan, Ph.D., M.P.H.
Assistant Professor
Behavioral and Community Health Sciences
Pitt Public Health
MedicalResearch.com: What is the background for this study?
Response: When taken as a daily pill, pre-exposure prophylaxis (PrEP) reduces the risk of getting HIV from sex by about 99%, according to the Centers for Disease Control and Prevention. However, adhering to a daily medication regimen doesn’t work for everyone for reasons that include cost and individual concerns about the biological consequences of long-term medication. Previous studies have shown that there are certain periods when some men who have sex with men may be more vulnerable to contracting HIV, including when traveling, on vacation, moving to a new city or after a break-up. Our team set out to explore whether these men might be more receptive to adhering to PrEP treatment during these times.
We followed 48 adult men from Pittsburgh or Boston who have sex with men in a pilot program to test the daily use of PrEP for 30 days that included an out-of-town vacation, with the men starting the medication seven days before the trip and continuing for at least seven days after vacation. The men were also given a brief session introducing them to the use of PrEP and discussion adherence.
Dr. Asgari[/caption]
Maryam M. Asgari, MD MPH
Professor
Department of Dermatology, Massachusetts General Hospital
Department of Population Medicine, Harvard Medical School
MedicalResearch.com: What is the background for this study? What are Topical Calcineurin Inhibitors used for?
Response: Topical calcineurin inhibitors (TCIs) are FDA approved for the treatment of atopic dermatitis (though they are used off-label to treat a wide range of inflammatory conditions of the skin, including psoriasis, seborrheic dermatitis, and contact dermatitis). There are currently two drugs available – tacrolimus and pimecrolimus – both of which carry a black box label warning users about the potential for increased skin cancer risk. The risk associated with keratinocyte carcinoma, the most common cancer (defined as basal cell carcinoma and squamous cell carcinoma), remains poorly defined because findings from large-scale post-marketing surveillance studies are lacking.
Dr. Reyes Gil[/caption]
Morayma Reyes Gil M.D., Ph.D.
Director of hematology and Coagulation Labs
Associate Professor, Pathology
Montefiore Medical Center and Albert Einstein School of Medicine
Bronx, NY 10467
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Antiphospholipid Syndrome is an entity caused by autoantibodies that cause arterial and venous thrombosis as well as miscarriages. During the COVID-19 pandemic, we tested 187 patients for Lupus anticoagulant (LA); 68 turned out to be COVID positive. 30 of the 68 COVID-positive patients were found to be positive for LA by the DRVVT test, and 17 of them were also determined to be positive by the hexagonal phospholipid neutralization STACLOT-LA test. Importantly, of the 30 patients who were LA positive, 19 had documented thrombosis (arterial and venous), an event rate of 63%, as compared with a rate of 34% (p = .03) for LA-negative patients.
We also checked CRP, an inflammatory marker known to affect the hexagonal phospholipid neutralization STACLOT-LA test. Although the mean CRP level was higher in patients testing positive for LA by DRVVT (14.4 vs 7.5 mg/dL; P < .01), patients with thrombosis did not have significantly higher CRP levels than those with no thrombosis. Hence, we adjusted for CRP, and LA was found to be independently associated with thrombosis (odds ratio, 4.39; 95% CI, 1.45-14.57; p= .01). No statistically significant difference was found by anticoagulation at the time of thrombosis, gender, race, ethnicity, ventilation, and mortality between patients who tested LA positive vs. negative.
Elizabeth Webb[/caption]
Elizabeth Webb, M.P.H
Physiotherapy Department
Calvary Public Hospital Bruce
Bruce, Australia
MedicalResearch.com: What is the background for this study?
Response: Our study showed that in patients with a history of leg swelling (chronic edema), compression therapy by a skilled lymphedema therapist reduced the risk of infection in the leg (cellulitis) by a huge 77%. With up to 47% of patients experiencing recurrence of cellulitis in their legs within 3 years, this result is a game-changer in terms of our approach to managing patients with leg swelling and recurrent cellulitis.
Until now, the use of prophylactic antibiotics to prevent cellulitis has been the only evidence-based practice. We know however, there are many reasons why avoidance of antibiotics is important within our community.
Dr. Deedwania[/caption]
Prakash Deedwania, MD, FACC,FAHA,FASH,FHFSA,FESC
Professor of Medicine, UCSF School of Medicine,
San Francisco
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This paper describes the findings form the FOURIER study, a very large study evaluating the efficacy of evolocumab, a PCSK9 inhibitor in patients with metabolic syndrome and preexisting atherosclerotic cardiovascular disease (ASCVD) who were already being treated with statins.
In this largest study of its kind of 27,000 patients we found that 60% of patients with ASCVD had metabolic syndrome. We also found that the presence of metabolic syndrome identified a higher risk of future cardiac & coronary events in these patients despite them receiving maximum tolerated doses of statin.
Furthermore, study treatment with evolocumab was efficacious in reducing the increased risk during the median follow up of nearly 3 years . Unlike treatment with statins there was no risk of new-onset diabetes with evolocumab, which was generally well tolerated. What was interesting thatpatients without metabolic syndrome had much less benefit with PCSK9 inhibition. These findings suggest that the presence of metabolic syndrome can help the clinicians identify the ASCVD patients who are most likely to benefit from treatment with PCSK9 inhibitors. This will be of great help for the cost containment of therapeutic strategy as PCSK9 inhibitors as a class are still quite expensive drugs.
Henry Mahncke, PhD
Dr. Walline[/caption]
Jeffrey J. Walline, OD PhD
Associate Dean for Research
The Ohio State University
Columbus, OH 43210-1240
MedicalResearch.com: What is the background for this study?
Response: Greater amounts of nearsightedness are related to higher risks of sight-threatening complications in adulthood, so anything we can do to slow the progression of nearsightedness in childhood can have meaningful benefits in the future.
As the prevalence of nearsightedness increases worldwide and affects approximately 1/3 of the people in the United States, a treatment that provides clear vision AND slows the progression of nearsightedness can have a profound effect.
Dr. Amy Kennedy, M.D., M.S
Clinician-Researcher Fellow, General Internal Medicine
University of Pittsburgh
MedicalResearch.com: What is the background for this study?
Response: UPMC uses a nucleic acid polymerase chain reaction (PCR) test for SARS-CoV-2 and specimen collection is done with a nasopharyngeal swab by trained clinicians. The health system developed its COVID-19 test in early March 2020 in anticipation of the tremendous need for diagnostic capabilities.
My colleagues and I worked with the Wolff Center at UPMC — the health system’s quality care and improvement center — to review the results of more than 30,000 COVID-19 tests performed on adult patients who received care through one of UPMC’s 40 academic, community and specialty hospitals, or 700 doctors’ offices and outpatient sites in Pennsylvania, New York and Maryland. The tests were performed between March 3 and May 3, 2020. Of those tests, 485 were repeated at least once.
Dr. Schreiber[/caption]
Darren Schreiber JD PhD
Senior Lecturer
Exeter
MedicalResearch.com: What is the background for this study?
Response: My co-authors and I saw an opportunity to match existing functional brain imaging data with publicly available voter registration data so that we could look for patterns that distinguish brain activity in nonpartisans from partisans. While a number of studies have found differences in both brain structure and function between partisans on the left and right and there is a massive amount of scholarship in political science on partisans and polarization, no brain imaging work had focused on nonpartisans. Around 40% of Americans do not affiliate with a political party and one important campaign strategy has been to persuade these voters to support party candidates. However many political scientists are skeptical about voters claims to be nonpartisans and will instead treat them as if they were merely covert partisans.
Dr. Cronstein[/caption]
Bruce N. Cronstein, MD
Paul R. Esserman Professor of Medicine
NYU School of Medicine
Director, NYU-H+H Clinical and Translational Science Institute
Director, Division of Translational Medicine
NYU Langone Health
New York, NY 10016
MedicalResearch.com: What is the background for this study?
Response: Osteoarthritis is the most common type of arthritis affecting about 10% of the adult population and 25% of the population over 60. We had previously found that adenosine, a molecule generated by nearly all cell types, is critical for maintaining cartilage health by activating specific adenosine receptors on the surface of cells (A2A receptors). Moreover, giving adenosine into the joint could prevent deterioration of cartilage (progression of osteoarthritis) in a rat model of osteoarthritis. Because people do not usually go for treatment of osteoarthritis until they have developed symptoms we asked whether administration of adenosine or adenosine that had been modified to be a more potent and specific stimulus for A2A receptors, carried in fat bubbles called liposomes, could reverse osteoarthritis after it had already started.
Dr. Batres[/caption]
Carlota Batres, PhD
Assistant Professor of Psychology
Franklin & Marshall College
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Many studies have examined how defendant characteristics influence jury decisions, but none have investigated the effect of makeup. We therefore examined how cosmetics influence jury decisions for young and middle-aged female defendants. We found that participants were more likely to assign guilty verdicts to middle-aged defendants than young defendants and when presented with makeup, male participants gave young defendants longer sentences and middle-aged defendants shorter sentences.
Dr. Davidson[/caption]
Karina W. Davidson, PhD, MA
Senior Vice President of Research, Northwell Health
Director, Center for Personalized Health, Feinstein Institutes for Medical Research
Dean of Academic Affairs & Professor, Feinstein Institutes for Medical Research
Donald and Barbara Zucker Professor in Health Outcomes, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: New York was epicenter for COVID-19 at the height of the pandemic, and Northwell Health, the largest health system in New York, did everything in its power to care for our sick community members but also care for and protect our frontline health care providers (HCPs) and 72,000 employees. We were fortunate enough to have not run out of PPE – from masks to gowns. Through our employee health team we were able to offer free antibody screenings and through the Northwell Health Research Consortium and the Feinstein Institutes for Medical Research we looked to use the data collected from our consented employees to determine the prevalence of antibodies.
We designed the study to not only identify the presence of antibodies but also key factors like demographics, in what capacity our providers worked on the frontlines and if they suspected infection. Our data helped identify the best practices Northwell Health – from PPE to care procedures - and others nationwide would need to do to keep our frontline workers safe.
Key takeaways from the research show that from April 20 to June 23, of the final consented sample of health care providers (40,329), 13 percent (5,523) tested positive for antibodies. The positive sample pool included 28.4 percent (11,468) nurses and 9.3 percent (3,746) physicians.
Dr. Kanter[/caption]
Genevieve Kanter, PhD
Leonard Davis Institute of Health Economic
Research Assistant Professor, General Internal Medicine,
Assistant Professor, Medical Ethics and Health Policy
Perelman School of Medicine
MedicalResearch.com: What is the background for this study?
Response: With the resurgence of COVID-19 and the likely seasonal resurgences, we were interested in whether those in low-income areas would be able to get access to the hospital care they might need. So we examined the distribution of ICU beds across the country and also looked at differences in the availability of ICU beds by household income in the community.
Dr. Gluckman[/caption]
Ty J. Gluckman, M.D., FACC
Providence St Joseph Health
Portland, Oregon
MedicalResearch.com: What is the background for this study?
Response: In spite of significant decreases in the incidence of coronary artery disease, an estimated 800,000 Americans are expected to be diagnosed with an acute myocardial infarction (AMI) this year. For large numbers of these patients, substantial benefit is afforded by early diagnosis and treatment. Accordingly, multiple campaigns have been launched over time to increase public awareness about the symptoms and signs of AMI and the need to seek immediate medical attention.
The COVID-19 pandemic has profoundly changed health care delivery worldwide. While early attention was disproportionately focused on efforts to “flatten the curve”, recent reports have revealed a disturbing finding—a substantial decrease in the hospitalization rate for AMI. Most worrisome among potential reasons for this has been reluctance of patients with an AMI to seek medical attention out of fear that they become infected with SARS-CoV-2.
To better understand the impacts associated with this, we performed a retrospective, cross-sectional study of all AMI hospitalizations in a large multistate health care system (Providence St. Joseph Health). We sought to define changes in AMI case rates, patient demographics, cardiovascular comorbidities, treatment approaches and in-hospital outcomes during the pandemic.
These findings suggest that despite having a more similar health care structure to other high spending health care systems, the U.S. health care system for those aged over 65 continues to be more expensive than comparators, although spending growth does appear to level off at older ages...
Dr. Gerstung[/caption]
Moritz Gerstung PhD
Group Leader: Computational cancer biology
EMBL-European Bioinformatics Institute
MedicalResearch.com: What is the background for this study?
Response: We have learned a lot in the last ten years about the molecular nature about various cancers thanks to the resources created by TCGA, ICGC and many other initiatives. Similarly, digital pathology has progressed hugely due to new AI algorithms. Yet it hasn’t been explored deeply how a cancer’s genetic makeup and its histopathological appearance are related. Here computers can be very helpful as they can process large amounts of digital microscopy slide images and test whether there are any recurrent histopathological patterns in relation to hundreds or thousands of genetic and other molecular abnormalities.
Dr. Heald-Sargent[/caption]
Taylor Heald-Sargent, M.D., Ph.D.
Ann & Robert H. Lurie Children’s Hospital
Chicago
MedicalResearch.com: What is the background for this study?
Response: Given the ongoing debate around the ability of children to transmit SARS-CoV-2, we noticed that our clinical data could address one of the prevalent assumptions. Some people postulated that the reason children have less severe infections with SARS-CoV-2 is because they are not able to replicate virus as much as adults and therefore may not transmit as readily.
Dr. Maher[/caption]
Dr. Pamela Maher, PhD
Senior Staff Scientist
Cellular Neurobiology Laboratory
Salk Institute for Biological Studies
Dr. Pamela Maher, is a senior staff scientist in the lab of Salk Professor David Schubert.
MedicalResearch.com: What is the background for this study?
Response: An estimated 5.2 million Americans over the age of 65 currently suffer from Alzheimer's disease (AD). There are no treatments that prevent, slow down or cure it. Moreover, the number of people suffering from it is expected to grow with the increase in the aging population. To meet this challenge, the NIH has set the ambitious goal of effectively treating AD by 2025. This will require the development of new disease-modifying drugs. Indeed, compared to cancer research, the drug discovery pipelines for AD are very limited. A missing key ingredient that is needed to re-invigorate AD-related drug discovery is new, promising AD drug targets.
Our lab is experienced in screening existing (natural) compounds for their protective abilities against several toxicities related to AD. Protective compounds are then further optimized to generate drug candidates with a favorable profile for the treatment of brain diseases. CMS121 is such a compound which is derived from fisetin, a natural product that can be found in many fruits and vegetables such as strawberries, grapes, cucumbers. Fisetin itself is not as potent and does not have the necessary chemical features to reach the brain efficiently. CMS121 is more potent and easily reaches the brain. We had previously shown that CMS121 improves several age-related cognitive dysfunctions.
Dr. Oliver-Williams[/caption]
Dr. Clare Oliver-Williams PhD
University of Cambridge
MedicalResearch.com: What is the background for this study?
Response: Women with PCOS are known to be at greater risk of CVD, however the some symptoms (menstrual irregularity) of PCOS are specific to reproductive age women. This raises the question of whether CVD risk varies across by age, which was the focus of my research with colleagues at the University of Copenhagen.
MedicalResearch.com: What should readers take away from your report?
Response: Women with PCOS were at 19% higher CVD risk than women without CVD, however once the association was stratified by age, there was no evidence for a higher CVD risk for women older than 50.
Dr. Sinha[/caption]
Pranay Sinha, MD
Research Fellow
Section of Infectious Diseases
Boston University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: In the early days of the COVID-19 pandemic there were no evidence-based treatments for severely ill patients infected with this virus. We formed an interdisciplinary group of physicians from departments of adult and pediatric infectious diseases, rheumatology, and pulmonary/critical care as well as clinical pharmacy specialists. Given some promising data from China, we instituted treatment with off-label IL-6 receptor inhibitors (tocilizumab and sarilumab). The rationale was to mitigate the exuberant immune response observed in some patients infected with SARS-CoV-2 (also called cytokine storm or cytokine release syndrome).
Quite quickly, we started noticing that giving the drug to our sickest patients wasn’t eliciting dramatic improvement. We reasoned that by the time patients were severely ill and requiring ventilators, the damage to their lungs from the cytokine storm had already taken place. It was like closing the barn door after the horse had already bolted.
[caption id="attachment_55022" align="alignleft" width="179"]
Dr. Hervé Perron[/caption]
Hervé Perron PhD
Chief Scientific Officer at GeNeuro
MedicalResearch.com: What is the background for this study?
Response: Human endogenous retroviruses (HERVs), remnants of ancestral viral genomic insertions, are known to represent 8% of the human genome and are associated with several pathologies. Certain proteins produced by HERVs have previously been found to be involved in pathogenic mechanisms linked to, e.g., multiple sclerosis (MS) or amyotrophic lateral sclerosis. However, despite previous results having shown an abnormal expression of HERV-W in patients with schizophrenia or bipolar disorder, the mechanisms involved in these psychiatric disorders are poorly understood.
Harvey Kaufman[/caption]
Harvey W. Kaufman, MD, MBA, FCAP
Senior Medical Director, Medical Informatics
Quest Diagnostics
Needham, MA
MedicalResearch.com: What is the background for this study?
Response: The COVID-19 pandemic has disrupted routine healthcare and in particular cancer screenings. We documented the impact on patients who were newly identified by cancer in the early months of the pandemic by analysis of Quest Diagnostics data.
MedicalResearch.com: What are the main findings?
Response: We saw a 46% decline in newly identified patients with six common types of cancer. In accordance to healthcare recommendations, many patients didn’t receive mammograms, colonoscopies, low-dose CT scans, and avoided physician visits for minor complaints. When these patients return, some will present with more advanced stages of cancer than they would have without the disruption of the pandemic.
Dr. Weisskopf[/caption]
Marc Weisskopf, PhD, ScD
Cecil K. and Philip Drinker Professor of Environmental Epidemiology and Physiology
Departments of Environmental Health and Epidemiology
Harvard T.H. Chan School of Public Health
Boston, MA 02115
MedicalResearch.com: What is the background for this study?
Response: There is a long history of health disparities by race. We were interested to see whether these also show up in professional football players, with the thought that perhaps the advantages that come with being an elite athlete in a sport (e.g. related to income, potential access to carte, prestige) might minimize health disparities.
Dr. Ferdows[/caption]
Nasim B. Ferdows, Ph.D.
Assistant Professor, Department of Health Administration and Policy
Hudson College of Public Health
The University of Oklahoma Health Sciences Center
Oklahoma City, OK
MedicalResearch.com: What is the background for this study?
Response: This half a century study of US senior men and women who died between 1968 and 2016 shows how disparities in the Black and White mortality of older US citizens have changed over time, as well as how the racial disparities differ in rural, suburban and urban areas.
Dupixent is a biologic therapy that works differently from existing therapies that treat atopic diseases[/caption]
MedicalResearch.com: What is the background for this announcement? What are the main indications for Dupixent?
Response: Until now, Dupixent 300 mg dose was available only in pre-filled syringe for administration. The approval of the pre-filled pen provides an additional, easy-to-use option for patients to self-administer Dupixent.
Dupixent is approved to treat patients aged 6 years and older with uncontrolled moderate-to-severe atopic dermatitis (AD) and can be used with or without topical treatments. Dupixent is also approved for use with other medicines for the maintenance treatment of uncontrolled moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years and older, and with other medicines for the maintenance treatment of uncontrolled chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults, respectively.
The pre-filled pen is approved for use in patients prescribed Dupixent who are 12 years of age and older across current indications, at the 300 mg dose.
Carl D. Regillo, MD, FACS
Chief, Retina Service
Wills Eye Hospital
MedicalResearch.com: What is the background for the Phase III Archway study? Would you briefly explain what Neovascular Age-Related Macular Degeneration means?
Genentech announced in late July the results from the Phase III Archway study evaluating Port Delivery System (PDS) with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD) which showed PDS enabled 98.4% of people to go six months between treatments, while achieving vision outcomes equivalent to those receiving monthly ranibizumab eye injections, a current standard of care.
AMD is a condition that affects the part of the eye that provides sharp, central vision needed for activities like reading and is a leading cause of blindness for people age 60 and over in the U.S. Neovascular AMD is an advanced form of AMD that can cause rapid and severe vision loss. Approximately 11 million people in the United States have some form of AMD and of those, about 1.1 million have nAMD.